Skip to main content
NewslettersWatchlist

Theratechnologies(TH-T)
TSX

Today's Change
Real-Time Last Update
Day Low4.36
Day High4.53
Open:4.47
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

TOP STORIES: Theratechnologies

Select a category then submit the form to load news
GlobeNewswire
Theratechnologies Announces Completion of Acquisition by Future Pak
GlobeNewswire
Theratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future Pak
GlobeNewswire
Theratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future Pak
Baystreet
Stocks in play: Theratechnologies Inc.
GlobeNewswire
Theratechnologies Announces Availability of EGRIFTA WR™ (tesamorelin) for injection to Reduce Excess Abdominal Fat in Adults with HIV and Lipodystrophy
GlobeNewswire
Theratechnologies Announces Independent Proxy Advisor Firms ISS and Glass Lewis Recommend Shareholders Vote “FOR” the Proposed Plan of Arrangement with Future Pak
GlobeNewswire
Theratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future Pak
GlobeNewswire
Theratechnologies Reports Financial Results for the Second Quarter 2025
The Globe and Mail
Small caps to watch: Biopharm stock surges on takeover deal, Cargojet wins contract extension, and more
Claude Vaillancourt, Research Associate, doing peptide synthesis in one of Theratechnologies' labs. Credit to Theratechnologies
GlobeNewswire
Theratechnologies to Announce Second Quarter 2025 Financial Results
GlobeNewswire
Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak
GlobeNewswire
Theratechnologies Reports on its Annual Meeting of Shareholders
Baystreet
Stocks in play: Theratechnologies Inc.
GlobeNewswire
Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV
The Globe and Mail
Small caps to watch: Cargojet, Well Health, Mullen Group and more
A Cargojet plane sits on the tarmac at the John C. Munro Hamilton International Airport in Hamilton, Ont., Friday, Feb. 23, 2024. THE CANADIAN PRESS/Nick Iwanyshyn
GlobeNewswire
Theratechnologies Provides Update on Sale Process
The Globe and Mail
Monday’s analyst upgrades and downgrades
Milk is seen in a refrigerator, marked with a sign indicating it is prepared in Canada, at a grocery store in Ottawa, on Wednesday, April 2, 2025.
GlobeNewswire
Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company
GlobeNewswire
Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements
Baystreet
Stocks in play: Theratechnologies Inc.
GlobeNewswire
Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA
GlobeNewswire
Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update
Baystreet
Futures Flat Awaiting Clarity on Tariffs
GlobeNewswire
Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy
Baystreet
Stocks in play: Theratechnologies Inc.
GlobeNewswire
Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI
GlobeNewswire
Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV
GlobeNewswire
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024
AI-generated - The Globe and Mail
Theratechnologies: Top 10 Undervalued Biotechnology Industry Stocks (TH)
GlobeNewswire
Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
GlobeNewswire
Theratechnologies Resumes Distribution of EGRIFTA SV®
The Globe and Mail
When will lagging health care stocks return to healthy growth?
Stethoscope, Charts and Graphs spreadsheet paper, Finance, Account, Statistics, Investment, Analytic research data economy spreadsheet and Business company concept.

Profile

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2025.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2025 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.